Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1981 2
1983 4
1985 1
1986 1
1987 3
1988 2
1989 2
1990 4
1997 2
1998 1
1999 1
2000 1
2002 1
2003 3
2005 2
2007 2
2008 1
2011 1
2012 3
2013 1
2014 4
2015 1
2016 4
2017 1
2018 1
2019 2
2020 1
2021 2
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

53 results

Results by year

Filters applied: . Clear all
Page 1
Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy.
Crews KR, Monte AA, Huddart R, Caudle KE, Kharasch ED, Gaedigk A, Dunnenberger HM, Leeder JS, Callaghan JT, Samer CF, Klein TE, Haidar CE, Van Driest SL, Ruano G, Sangkuhl K, Cavallari LH, Müller DJ, Prows CA, Nagy M, Somogyi AA, Skaar TC. Crews KR, et al. Among authors: callaghan jt. Clin Pharmacol Ther. 2021 Oct;110(4):888-896. doi: 10.1002/cpt.2149. Epub 2021 Feb 9. Clin Pharmacol Ther. 2021. PMID: 33387367 Free PMC article. Review.
Olanzapine. Pharmacokinetic and pharmacodynamic profile.
Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM. Callaghan JT, et al. Clin Pharmacokinet. 1999 Sep;37(3):177-93. doi: 10.2165/00003088-199937030-00001. Clin Pharmacokinet. 1999. PMID: 10511917 Review.
PharmGKB summary: uric acid-lowering drugs pathway, pharmacodynamics.
McDonagh EM, Thorn CF, Callaghan JT, Altman RB, Klein TE. McDonagh EM, et al. Among authors: callaghan jt. Pharmacogenet Genomics. 2014 Sep;24(9):464-76. doi: 10.1097/FPC.0000000000000058. Pharmacogenet Genomics. 2014. PMID: 24915143 Free PMC article. Review. No abstract available.
Response to Gammal et al.
Vassy JL, Stone A, Callaghan JT, Mendes M, Meyer LJ, Pratt VM, Przygodzki RM, Scheuner MT, Wang-Rodriguez J, Schichman SA; VHA Clinical Pharmacogenetics Subcommittee. Vassy JL, et al. Among authors: callaghan jt. Genet Med. 2019 Aug;21(8):1888-1889. doi: 10.1038/s41436-018-0422-9. Epub 2019 Jan 12. Genet Med. 2019. PMID: 30635623 No abstract available.
Implementation of a pharmacogenomics consult service to support the INGENIOUS trial.
Eadon MT, Desta Z, Levy KD, Decker BS, Pierson RC, Pratt VM, Callaghan JT, Rosenman MB, Carpenter JS, Holmes AM, McDonald CA, Benson EA, Patil AS, Vuppalanchi R, Gufford BT, Dave N, Robarge JD, Hyder MA, Haas DM, Kreutz RP, Dexter PR, Skaar TC, Flockhart DA. Eadon MT, et al. Among authors: callaghan jt. Clin Pharmacol Ther. 2016 Jul;100(1):63-6. doi: 10.1002/cpt.347. Epub 2016 Mar 31. Clin Pharmacol Ther. 2016. PMID: 26850569 Free PMC article. Review.
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update.
Karnes JH, Rettie AE, Somogyi AA, Huddart R, Fohner AE, Formea CM, Ta Michael Lee M, Llerena A, Whirl-Carrillo M, Klein TE, Phillips EJ, Mintzer S, Gaedigk A, Caudle KE, Callaghan JT. Karnes JH, et al. Among authors: callaghan jt. Clin Pharmacol Ther. 2021 Feb;109(2):302-309. doi: 10.1002/cpt.2008. Epub 2020 Sep 6. Clin Pharmacol Ther. 2021. PMID: 32779747 Free PMC article. Review.
Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update.
Crews KR, Gaedigk A, Dunnenberger HM, Leeder JS, Klein TE, Caudle KE, Haidar CE, Shen DD, Callaghan JT, Sadhasivam S, Prows CA, Kharasch ED, Skaar TC; Clinical Pharmacogenetics Implementation Consortium. Crews KR, et al. Among authors: callaghan jt. Clin Pharmacol Ther. 2014 Apr;95(4):376-82. doi: 10.1038/clpt.2013.254. Epub 2014 Jan 23. Clin Pharmacol Ther. 2014. PMID: 24458010 Free PMC article. Review.
A pharmacokinetic profile of nizatidine in man.
Callaghan JT, Bergstrom RF, Rubin A, Chernish S, Crabtree R, Knadler MP, Obermeyer B, Offen WW, Schneck DW, Aronoff G, et al. Callaghan JT, et al. Scand J Gastroenterol Suppl. 1987;136:9-17. doi: 10.3109/00365528709094480. Scand J Gastroenterol Suppl. 1987. PMID: 2892261 Review.
The INGENIOUS trial: Impact of pharmacogenetic testing on adverse events in a pragmatic clinical trial.
Eadon MT, Rosenman MB, Zhang P, Fulton CR, Callaghan JT, Holmes AM, Levy KD, Gupta SK, Haas DM, Vuppalanchi R, Benson EA, Kreutz RP, Tillman EM, Shugg T, Pierson RC, Gufford BT, Pratt VM, Zang Y, Desta Z, Dexter PR, Skaar TC. Eadon MT, et al. Among authors: callaghan jt. Pharmacogenomics J. 2023 Nov;23(6):169-177. doi: 10.1038/s41397-023-00315-w. Epub 2023 Sep 9. Pharmacogenomics J. 2023. PMID: 37689822 Clinical Trial.
The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective.
Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, Kumar G, McLeod J, Obach SR, Roberts S, Roe A, Shah A, Snikeris F, Sullivan JT, Tweedie D, Vega JM, Walsh J, Wrighton SA; Pharmaceutical Research and Manufacturers of America Drug Metabolism/Clinical Pharmacology Technical Working Groups. Bjornsson TD, et al. Among authors: callaghan jt. J Clin Pharmacol. 2003 May;43(5):443-69. J Clin Pharmacol. 2003. PMID: 12751267 Review.
53 results